L. Bangio

发表

Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta 2-glycoprotein I.

Y. Shoenfeld, B. Gilburd, D. Harats, 2004, Cardiovascular research.

Systemic Administration of a Conditionally Replicating Adenovirus, Targeted to Angiogenesis, Reduced Lung Metastases Burden in Cotton Rats

I. Barshack, D. Harats, S. Greenberger, 2009, Clinical Cancer Research.

Transcription-controlled gene therapy against tumor angiogenesis.

I. Barshack, D. Harats, D. Wallach, 2004, The Journal of clinical investigation.

Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK

I. Barshack, D. Harats, D. Ben-Shushan, 2009, Cancer biology & therapy.

Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors

A. Brenner, E. Borden, D. Harats, 2013, Clinical Cancer Research.

VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme

A. Brenner, Jessica R. Miller, D. Cavazos, 2015, Journal of Neuro-Oncology.

Abstract 3283: VB-111 a novel anti-angiogenic vector and a promising treatment for metastatic cancer in combination with other anticancer drugs

Y. Cohen, E. Breitbart, L. Bangio, 2011 .

Endothelial-targeted Gene Transfer of Hypoxia-inducible Factor-1α Augments Ischemic Neovascularization Following Systemic Administration.

I. Barshack, D. Harats, E. Feige, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Activation of C-transactivation domain is essential for optimal HIF-1 alpha-mediated transcriptional and angiogenic effects.

D. Harats, A. Shaish, R. Tal, 2008, Microvascular research.

Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial.

P. Wen, L. Freedman, A. Brenner, 2016 .